{"acquisitions":[],"changes":[],"country":"DE","description":"ITM Radiopharma develops, manufactures, and supplies targeted radiopharmaceuticals including ITM-11 (177Lu-edotreotide) for gastroenteropancreatic neuroendocrine tumors. It treats patients with NETs, glioblastoma, osteosarcoma, and folate-receptor cancers. ITM runs its own GMP isotope production and beat Afinitor in Phase III.","domain":"itm-rp.com","employees":null,"founded":2011,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":48.137108,"lng":11.575382,"location":"Munich, Germany","multiples":[],"name":"ITM Radiopharma","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":203040000,"connectionsAmong":[],"currency":"EUR","date":"2024-06-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"itm-rp-com-2024-06-01-strategic","source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-22","status":"attributed","url":null},"status":"attributed","type":"strategic","url":null}],"slug":"itm-rp-com","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-22","status":"attributed","url":null},{"fact":"existence","publisher":"itm-rp.com","retrievedAt":"2026-05-22","status":"self-reported","url":"https://itm-rp.com"},{"fact":"description","publisher":"itm-rp.com","retrievedAt":"2026-05-22","status":"self-reported","url":"https://itm-rp.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":378000000,"traction":[],"updatedAt":"2026-05-22","valuations":[]}